(Q24250287)

https://api.crossref.org/works/10.1002%2F14651858.CD002132

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002132

Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002132

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002132

Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002132

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002132

Low-molecular-weight heparin in the treatment of patients with venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002132

Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002132

Elucidation of the role of plaque instability and rupture in acute coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002132

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002132

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002132

Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002132

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002132

Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002132

7 January 2021

Incidence, outcome and prediction of early clinical events following percutaneous transluminal coronary angioplasty. A comparison between treatment with reviparin and unfractionated heparin/placebo (results of a substudy of the REDUCE trial)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002132

7 January 2021

Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002132

7 January 2021

Aspirin, heparin, or both to treat acute unstable angina

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002132

7 January 2021

A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002132

7 January 2021

Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002132

7 January 2021

ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002132

7 January 2021

Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002132

7 January 2021